Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase II clinical trial to treat solid tumors. The company also offers INCB001158, an oral inhibitor of arginase that is in Phase I/II clinical trial for the treatment of hematology and oncology. It has a license agreement with Mars, Inc. to develop and commercialize Symbioscience's portfolio of arginase inhibitors for use in human healthcare; and license and research agreement with High Point Pharmaceuticals, LLC and TransTech Pharma LLC to develop and commercialize hexokinase II inhibitors. The company also has clinical trial collaboration with Bristol-Myers Squibb Company to evaluate nivolumab in combination with CB-839 in cell renal cell carcinoma. In addition, it has a collaboration and license agreement with Incyte Corporation for the research, development, and commercialization of INCB001158, a small molecule arginase inhibitor for the treatment of hematology and oncology. Calithera Biosciences, Inc. was founded in 2010 and is headquartered in South San Francisco, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone650-870-1000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$25.95 million
Profitability
Miscellaneous
Employees73
OptionableOptionable
Calithera Biosciences (NASDAQ:CALA) Frequently Asked Questions
What is Calithera Biosciences' stock symbol?
Calithera Biosciences trades on the NASDAQ under the ticker symbol "CALA."
How were Calithera Biosciences' earnings last quarter?
Calithera Biosciences Inc (NASDAQ:CALA) issued its quarterly earnings results on Wednesday, November, 7th. The biotechnology company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.40) by $0.12. Calithera Biosciences had a negative net margin of 90.65% and a negative return on equity of 31.73%. View Calithera Biosciences' Earnings History.
When is Calithera Biosciences' next earnings date?
What price target have analysts set for CALA?
1 brokerages have issued 12-month target prices for Calithera Biosciences' shares. Their forecasts range from $10,000,000.00 to $0.00. On average, they anticipate Calithera Biosciences' stock price to reach $0.00 in the next year. This suggests that the stock has a possible downside of 100.0%. View Analyst Price Targets for Calithera Biosciences.
What is the consensus analysts' recommendation for Calithera Biosciences?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Calithera Biosciences in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Calithera Biosciences.
Has Calithera Biosciences been receiving favorable news coverage?
Media headlines about CALA stock have been trending positive recently, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Calithera Biosciences earned a news impact score of 2.3 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 6.0 out of 10, indicating that recent press coverage is somewhat likely to have an effect on the company's share price in the near future.
Who are some of Calithera Biosciences' key competitors?
Some companies that are related to Calithera Biosciences include G1 Therapeutics (GTHX), Apellis Pharmaceuticals (APLS), Inflarx (IFRX), Arvinas (ARVN), Intra-Cellular Therapies (ITCI), Y-mAbs Therapeutics (YMAB), Evolus (EOLS), ANI Pharmaceuticals (ANIP), Dicerna Pharmaceuticals (DRNA), Dynavax Technologies (DVAX), Principia Biopharma (PRNB), Omeros (OMER), Cara Therapeutics (CARA), Rocket Pharmaceuticals (RCKT) and Revance Therapeutics (RVNC).
Who are Calithera Biosciences' key executives?
Calithera Biosciences' management team includes the folowing people:
- Dr. Susan M. Molineaux, Co-Founder, CEO, Pres & Director (Age 65)
- Ms. Sumita Ray, Sr. VP, Gen. Counsel & Chief Compliance Officer (Age 45)
- Dr. Keith Orford, Chief Medical Officer (Age 47)
- Ms. Stephanie Wong, Sr. VP of Fin. & Sec. (Age 45)
- Ms. Jennifer McNealey, VP of Investor Relations & Strategy
Who are Calithera Biosciences' major shareholders?
Calithera Biosciences' stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (8.00%), Dimensional Fund Advisors LP (3.26%), Northern Trust Corp (0.92%), Geode Capital Management LLC (0.91%), Bank of New York Mellon Corp (0.33%) and Bank of America Corp DE (0.24%). Company insiders that own Calithera Biosciences stock include Adage Capital Partners Gp, LL, Curtis Hecht and Keith Orford. View Institutional Ownership Trends for Calithera Biosciences.
Which institutional investors are selling Calithera Biosciences stock?
CALA stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Hikari Power Ltd, Bank of New York Mellon Corp, Acadian Asset Management LLC, Two Sigma Investments LP, New York State Common Retirement Fund, Barclays PLC and Northern Trust Corp. View Insider Buying and Selling for Calithera Biosciences.
Which institutional investors are buying Calithera Biosciences stock?
CALA stock was purchased by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Geode Capital Management LLC, Alps Advisors Inc., Paloma Partners Management Co, Two Sigma Advisers LP, Bank of America Corp DE, Rhumbline Advisers and Virtu Financial LLC. View Insider Buying and Selling for Calithera Biosciences.
How do I buy shares of Calithera Biosciences?
Shares of CALA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Calithera Biosciences' stock price today?
One share of CALA stock can currently be purchased for approximately $5.36.
How big of a company is Calithera Biosciences?
Calithera Biosciences has a market capitalization of $204.36 million and generates $25.95 million in revenue each year. The biotechnology company earns $-27,820,000.00 in net income (profit) each year or ($0.84) on an earnings per share basis. Calithera Biosciences employs 73 workers across the globe.
What is Calithera Biosciences' official website?
How can I contact Calithera Biosciences?
Calithera Biosciences' mailing address is 343 OYSTER POINT BLVD. SUITE 200, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-870-1000 or via email at [email protected]
MarketBeat Community Rating for Calithera Biosciences (NASDAQ CALA)
MarketBeat's community ratings are surveys of what our community members think about Calithera Biosciences and other stocks. Vote "Outperform" if you believe CALA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CALA will underperform the S&P 500 over the long term. You may vote once every thirty days.
